Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Meropenem

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 05, 2027 · 188 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Meropenem, ATC J01DH02

52/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

52 / 100

Złożoność

48 / 100

Czynniki ryzyka

Paper submissions are only treated as timely if the complete and correct originals arrive by the 10th of the month afte...

The buyer states that only pharmaceutical companies are eligible as potential contract partners.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Non-exclusive rebate agreements for the medicinal product Meropenem, ATC J01DH02.
  • Open-house model with identical, pre-set contract terms for all eligible pharmaceutical companies.
Pokaż pełne podsumowanie

This is an open-house pharmaceutical rebate agreement for Meropenem (ATC J01DH02) offered by AOK Bayern. It is not a competitive award procedure: the buyer states that all interested pharmaceutical companies meeting the stated suitability requirement can join on identical, non-negotiable terms. No contract value is stated. Submission is possible electronically via DTVP with a qualified electronic signature or in paper form in duplicate originals. The deadline for receipt of complete and correct documents is 2027-03-05 11:00, with monthly contract start mechanics described in the notice.

Ryzyka

Paper submissions are only treated as timely if the complete and correct originals arrive by the 10th of the month afte...

The buyer states that only pharmaceutical companies are eligible as potential contract partners.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • A signed declaration of reliability/suitability must be submitted.
  • The signed contract and the completed annex 'Determination of the medicinal products covered by the contract' must be submitted.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Meropenem

Single lot for non-exclusive open-house rebate agreements for the pharmaceutical product Meropenem, ATC J01DH02. The notice says the contract terms are identical and not individually negotiable. Performance is in Germany, specifically Bavaria (DE212).

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Apr 2025 - Apr 2027

Kategoria

Pharmaceutical products

Termin

Deadline Mar 05, 2027

Szczegóły zamówienia

Data publikacji
18 Mar 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
176004-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30